A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies

Trial Profile

A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs KO 947 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Kura Oncology
  • Most Recent Events

    • 15 May 2017 According to a Kura Oncology media release, data from this trial are expected in 2018.
    • 07 Apr 2017 According to a Kura Oncology media release, company has identified two tumor-specific cohorts, non-small cell lung cancer with mutations in RAS or BRAF and squamous cell carcinomas as potential extension cohortsin this trial.
    • 07 Apr 2017 According to a Kura Oncology media release, the first patient has been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top